MarketPulse

erythropoietic protoporphyria

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Plummets After FDA Rejects Bitopertin Application

Disc Medicine stock tumbled 30% after FDA rejected bitopertin drug application, prompting securities fraud investigation by Pomerantz LLP.
IRONsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Pomerantz Llp

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.
IRONsecurities fraudclass action lawsuit